Website
News25/Ratings1
News · 26 weeks31+75%
2025-10-262026-04-19
Mix2190d
- Other10(48%)
- SEC Filings8(38%)
- Offering3(14%)
Latest news
25 items- SECBioRestorative Therapies Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - BioRestorative Therapies, Inc. (0001505497) (Filer)
- PRBioRestorative Therapies Announces Strategic Partnership with Global Dermatology Leader Dr. David J. Goldberg to Lead Clinical Evaluation and Seek Multi-Channel Adoption of Its Regenerative BioCosmeceutical PlatformCollaboration establishes an independent clinical validation pathway, expands access to influential physician networks, and strengthens the foundation for possible broad commercial growth across professional, biologic dermal, and consumer channels MELVILLE, N.Y., April 21, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company") (NASDAQ:BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announced a strategic partnership with David J. Goldberg, M.D., J.D., internationally recognized as one of the foremost innovators in laser dermatology, regenerative aesthetics, and clinical researc
- SECSEC Form POS AM filed by BioRestorative Therapies Inc.POS AM - BioRestorative Therapies, Inc. (0001505497) (Filer)
- SECSEC Form DEF 14A filed by BioRestorative Therapies Inc.DEF 14A - BioRestorative Therapies, Inc. (0001505497) (Filer)
- PRBioRestorative Therapies Announces Strategic Collaboration with 203 Creates to Build and Commercialize Biocosmeceutical PlatformPartnership to drive brand architecture, go-to-market execution, and global launch of the Company's product portfolio bridging biotechnology and premium skincare MELVILLE, N.Y., April 07, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company") (NASDAQ:BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announced a strategic collaboration with 203 Creates, LLC, a Stamford, Connecticut-based firm specializing in the development, marketing, and growth of luxury, premium, and science-backed brands. The collaboration is designed to advance BioRestorative's biocosmeceutical platform by
- SECSEC Form PRE 14A filed by BioRestorative Therapies Inc.PRE 14A - BioRestorative Therapies, Inc. (0001505497) (Filer)
- PRBioRestorative Therapies Reports Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc DiseaseData showed 50% or more of patients reporting >50% improvement in key pain and function scales No adverse events related to dose-limiting toxicities associated with hypoxic-cultured mesenchymal stem cells Presented at the 2026 Orthopaedic Research Society Annual Meeting MELVILLE, N.Y., March 30, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company") (NASDAQ:BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announced blinded data from its Phase 2 clinical trial evaluating hypoxic-cultured mesenchymal stem cells for the treatment of chronic lumbar disc disease, with 50% or more
- SECSEC Form 10-K filed by BioRestorative Therapies Inc.10-K - BioRestorative Therapies, Inc. (0001505497) (Filer)
- PRBioRestorative Therapies to Present Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc DiseaseNew blinded data from ~45 patients to date in key pain and function scales and safety and tolerability of the Company's proprietary hypoxic-cultured mesenchymal stem cells to be unveiled on March 28th at the 2026 Orthopaedic Research Society Annual Meeting MELVILLE, N.Y., March 19, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company") (NASDAQ:BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announced that new blinded data on approximately 45 patients from its Phase 2 clinical trial evaluating hypoxic-cultured mesenchymal stem cells for the treatment of chronic lumbar disc dise
- PRBioRestorative Therapies, Inc. to Participate in the Be+Well Beauty and Wellness Show in New York City, March 8-10, 2026Company to engage industry partners and distribution channels as part of expanding BioCosmeceutical commercialization strategy MELVILLE, N.Y., March 05, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a late stage clinical regenerative medicine innovator focused on stem cell-based therapies and products, today announced that members of its commercial leadership team will participate in the Be+Well Beauty and Wellness Show taking place March 8-10, 2026 at the Javits Center in New York City. The Be+Well trade show is one of the largest professional beauty, spa, and wellness trade events in the U.S., bringing together 35,000+
- PRBioRestorative Therapies, Inc. Issues Letter to Shareholders Highlighting Major Milestones, Regulatory Alignment, Clinical Execution and Capital StrategyCompany is well positioned following positive FDA Type B meeting outcome, fully enrolled Phase 2 trial for its lead clinical program, and recent $5 million public offering, as commercial operation continues to build momentum MELVILLE, N.Y., March 04, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a late stage clinical regenerative medicine innovator focused on stem cell-based therapies and products, today issued the following letter to shareholders from Chief Executive Officer Lance Alstodt: To our shareholders and stakeholders, The first quarter of 2026 marks a pivotal period for BioRestorative Therapies. We have achie
- PRBioRestorative Expands Global Protection for ThermoStem®, a Potentially Longer-Lasting and Safer Cell-Based Alternative to GLP-1 DrugsGLP-1 drugs have captured global attention, but they come with limitations — tolerability issues, muscle mass loss, and potential cardiovascular risks. BioRestorative believes its cell-based therapeutic candidates may offer the potential for longer-lasting efficacy with improved safety and dosing advantages. MELVILLE, N.Y., Feb. 24, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a late stage clinical regenerative medicine innovator focused on stem cell-based therapies and products, today announced that IP Australia, the intellectual property branch of the Australian government, has allowed Patent Application No. 202026566
- SECBioRestorative Therapies Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - BioRestorative Therapies, Inc. (0001505497) (Filer)
- PRBioRestorative Announces Closing of $5.0 Million Public OfferingMELVILLE, N.Y., Feb. 13, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a late stage clinical regenerative medicine innovator focused on stem cell-based therapies and products, today announced the closing of its previously announced public offering of 14,285,715 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 14,285,715 shares of common stock, at a combined public offering price of $0.35 per share (or pre-funded warrant in lieu thereof) and accompanying warrants. The warrants have an exercise price of $0.35 per share, are immediately exercisable and will expire five years from
- SECSEC Form 424B4 filed by BioRestorative Therapies Inc.424B4 - BioRestorative Therapies, Inc. (0001505497) (Filer)
- SECSEC Form EFFECT filed by BioRestorative Therapies Inc.EFFECT - BioRestorative Therapies, Inc. (0001505497) (Filer)
- PRBioRestorative Announces Pricing of $5.0 Million Public OfferingMELVILLE, N.Y., Feb. 11, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a late stage clinical regenerative medicine innovator focused on stem cell-based therapies and products, today announced the pricing of a public offering of 14,285,715 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 14,285,715 shares of common stock, at a combined public offering price of $0.35 per share (or pre-funded warrant in lieu thereof) and accompanying warrants. The warrants will have an exercise price of $0.35 per share and will be exercisable immediately upon issuance and will expire five years f
- PRBioRestorative Announces Positive Outcome from Type B Meeting with FDABioRestorative completed a Type B meeting with the U.S. Food and Drug Administration ("FDA") regarding a potential accelerated Biologics License Application ("BLA") approval pathway for the Fast-Track-Designated BRTX-100 program for the treatment of chronic lumbar disc disease ("cLDD")Consistent positive clinical safety endpoints from BioRestorative's ongoing 99 patient Phase 2 clinical trial of BRTX-100 in cLDD were discussed in the meeting and the FDA did not raise any clinical safety concerns FDA endorsed the proposed Phase 3 study design (i.e., outcome assessments, dosing strategy, and eligibility criteria), sample size, and powering assumptions pending final review of Phase 3 investigat
- SECAmendment: SEC Form S-1/A filed by BioRestorative Therapies Inc.S-1/A - BioRestorative Therapies, Inc. (0001505497) (Filer)
- PRBioRestorative Completes Patient Enrollment in Landmark Phase 2 Trial of BRTX-100 for Chronic Lumbar Disc DiseaseLargest FDA-authorized Phase 2 cell therapy trial conducted in chronic lumbar disc diseaseThe study has enrolled a total of 99 participants, each of whom was randomized to receive either BRTX-100 or placeboProspective, randomized, double-blind, sham-controlled single-disc study — gold-standard clinical designEnrollment completion strengthens regulatory pathway toward Phase 3 and potential BLA filing MELVILLE, N.Y., Feb. 10, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a late stage clinical regenerative medicine innovator focused on stem cell-based therapies and products, today announced completion of patient enrollment
- SECSEC Form S-1 filed by BioRestorative Therapies Inc.S-1 - BioRestorative Therapies, Inc. (0001505497) (Filer)
- SECSEC Form 424B3 filed by BioRestorative Therapies Inc.424B3 - BioRestorative Therapies, Inc. (0001505497) (Filer)
- SECSEC Form EFFECT filed by BioRestorative Therapies Inc.EFFECT - BioRestorative Therapies, Inc. (0001505497) (Filer)
- SECSEC Form S-8 filed by BioRestorative Therapies Inc.S-8 - BioRestorative Therapies, Inc. (0001505497) (Filer)
- SECSEC Form S-1 filed by BioRestorative Therapies Inc.S-1 - BioRestorative Therapies, Inc. (0001505497) (Filer)